Treatment Options for Insomnia-Pharmacodynamics of Zolpidem Extended-Release to Benefit Next-Day Performance

References

• Ancoli-Israel S, Roth T. Characteristics of insomnia in the United States: results of the 1991 National Sleep Foundation Survey. I. Sleep. 1999; 22(suppl 2): S347–S353.
   PubMed Web of Science ®Google Scholar
• Ohayon MM. Epidemiology of insomnia: what we know and what we still need to learn. Sleep Med Rev. 2002; 6(2): 97–111.
   PubMed Web of Science ®Google Scholar
• Drake CL, Roehrs T, Roth T. Insomnia causes, consequences, and therapeutics: an overview. Depress Anxiety. 2003; 18(4): 163–176.
   PubMed Web of Science ®Google Scholar
• Hohagen F, Kappler C, Schramm E, Riemann D, Weyerer S, Berger M. Sleep onset insomnia, sleep maintaining insomnia and insomnia with early morning awakening—temporal stability of subtypes in a longitudinal study on general practice attenders. Sleep. 1994; 17(6): 551–554.
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Washington, DC: American Psychiatric Association; 2002.
   Google Scholar
• Walsh JK. Pharmacologic management of insomnia. J Clin Psychiatry. 2004; 65(suppl 16): 41–45.
   PubMedGoogle Scholar
• Nissen C, Kloepfer C, Nofzinger EA, Feige B, Voderholzer U, Riemann D. Impaired sleep-related memory consolidation in primary insomnia—a pilot study. Sleep. 2006; 29(8): 1068–1073.
   PubMedGoogle Scholar
• Varkevisser M, Kerkhof GA. Chronic insomnia and performance in a 24-h constant routine study. J Sleep Res. 2005; 14(1): 49–59.
   PubMedGoogle Scholar
• Rosenthal LD, Meixner RM. Psychological status and levels of sleepiness-alertness among patients with insomnia. CNS Spectr. 2003; 8(2): 114–118.
   PubMedGoogle Scholar
• Lichstein KL, Means MK, Noe SL, Aguillard RN. Fatigue and sleep disorders. Behav Res Ther. 1997; 35(8): 733–740.
   PubMed Web of Science ®Google Scholar
• Mellinger GD, Baiter MB, Uhlenhuth EH. Insomnia and its treatment. Prevalence and correlates. Arch Gen Psychiatry. 1985; 42(2): 225–232.
   PubMedGoogle Scholar
• Katz DA, McHorney CA. The relationship between insomnia and health-related quality of life in patients with chronic illness. J Fam Pract. 2002; 51 (3): 229–235.
   PubMed Web of Science ®Google Scholar
• Ohayon MM, Caulet M, Philip P, Guilleminault C, Priest RG. How sleep and mental disorders are related to complaints of daytime sleepiness. Arch Intern Med. 1997; 157(22): 2645–2652.
   PubMedGoogle Scholar
• Walsh JK, Engelhardt CL. The direct economic costs of insomnia in the United States for 1995. Sleep. 1999; 22(suppl 2): S386–S393.
   PubMed Web of Science ®Google Scholar
• Simon GE, VonKorff M. Prevalence, burden, and treatment of insomnia in primary care. Am J Psychiatry. 1997; 154(10): 1417–1423.
   PubMed Web of Science ®Google Scholar
• Gottlieb DJ, Punjabi NM, Newman AB, et al. Association of sleep time with diabetes mellitus and impaired glucose tolerance. Arch Intern Med. 2005; 165(8): 863–867.
   PubMedGoogle Scholar
• Schwartz S, McDowell Anderson W, Cole SR, Cornoni-Huntley J, Hays JC, Blazer D. Insomnia and heart disease: a review of epidemiologic studies. J Psychosom Res. 1999; 47(4): 313–333.
   PubMed Web of Science ®Google Scholar
• Tsuno N, Besset A, Ritchie K. Sleep and depression. J Clin Psychiatry. 2005; 66(10): 1254–1269.
   PubMed Web of Science ®Google Scholar
• Ford DE, Kamerow DB. Epidemiologic study of sleep disturbances and psychiatric disorders. An opportunity for prevention? JAMA. 1989; 262(11): 1479–1484.
   PubMed Web of Science ®Google Scholar
• Roth T. Prevalence, associated risks, and treatment patterns of insomnia. J Clin Psychiatry. 2005; 66(suppl 9): 10–13; quiz 42–43.
   PubMedGoogle Scholar
• Stein MD, Friedmann PD. Disturbed sleep and its relationship to alcohol use. SubstAbus. 2005; 26(1): 1–13.
   PubMedGoogle Scholar
• Roth T, Roehrs T, Zorick F, Conway W. Pharmacological effects of sedative-hypnotics, narcotic analgesics, and alcohol during sleep. Med Clin North Am. 1985; 69(6): 1281–1288.
   PubMedGoogle Scholar
• Norström T, Ramstedt M. Mortality and population drinking: a review of the literature. Drug Alcohol Rev. 2005; 24(6): 537–547.
   PubMed Web of Science ®Google Scholar
• Ambien CRTM(Zolpidem tartrate extended release) CIV [package insert], Bridgewater, NJ: sanofi-aventis. http://products.sanofi-aventis.us/ambien_cr/ambiencr.html. Acccessed July 2008.
   Google Scholar
• AmbienTM (Zolpidem tartrate) CIV [package insert], Bridgewater, NJ: sanofi-aventis. http://products.sanofi-aventis.us/ambien/ambien.pdf. Accessed July 2008.
   Google Scholar
• LUNESTATM (eszopiclone) [package insert], Marlborough, MA: Sepracor, Inc. http://www.lunesta.com/PostedApprovedLabelingText.pdf. Accessed July 2008.
   Google Scholar
• Sonata® CIV (zaleplon) [package insert], Bristol, TN: King Pharmaceuticals, Inc. http://www.kingpharm.com/kingpharm/uploads/pdf_inserts/Sonata_PI_and_MedGuide.pdf. Accessed July 2008.
   Google Scholar
• National Institutes of Health. National Institutes of Health State of the Science Conference statement on manifestations and management of chronic insomnia in adults. Sleep. 2005; 28(9): 1049–1057.
   PubMed Web of Science ®Google Scholar
• Sproule BA, Busto UE, Buckle C, Herrmann N, Bowles S. The use of non-prescription sleep products in the elderly. Int J Geriatr Psychiatry. 1999; 14(10): 851–857.
   PubMed Web of Science ®Google Scholar
• Winkelman J, Pies R. Current patterns and future directions in the treatment of insomnia. Ann Clin Psychiatry. 2005; 17(1): 31–40.
   PubMedGoogle Scholar
• Leonard BE. Serotonin receptors and their function in sleep, anxiety disorders and depression. Psychother Psychosom. 1996; 65(2): 66–75.
   PubMedGoogle Scholar
• RozeremTM (ramelteon) [package insert], Deerfield, IL: Takeda Pharmaceuticals America, Inc. http.V/www.rozerem.com/PI_l.aspx. Accessed July 2008.
   Google Scholar
• Roth T, Seiden D, Sainati S, Wang-Weigand S, Zhang J, Zee P. Effects of ramelteon on patient-reported sleep latency in older adults with chronic insomnia. Sleep Med. 2006; 7(4): 312–318.
   PubMed Web of Science ®Google Scholar
• Erman M, Seiden D, Zammit G, Sainati S, Zhang J. An efficacy, safety, and dose-response study of Ramelteon in patients with chronic primary insomnia. Sleep Med. 2006; 7(1): 17–24.
   PubMed Web of Science ®Google Scholar
• Turek FW, Gillette MU. Melatonin, sleep, and circadian rhythms: a rationale for development of specific melatonin agonists. Sleep Med. 2004; 5(6): 523–532.
   PubMed Web of Science ®Google Scholar
• Ebert B, Wafford KA, Deacon S. Treating insomnia: current and investigational pharmacological approaches. Pharmacol Ther. 2006; 112(3): 612–629.
   PubMed Web of Science ®Google Scholar
• Kales A, Bixler EO, Soldatos CR, Vela-Bueno A, Jacoby J, Kales JD. Quazepam and flurazepam: long-term use and extended withdrawal. Clin Pharmacol Ther. 1982; 32(6): 781–788.
   PubMedGoogle Scholar
• Tansella CZ, Tansella M, Lader M. A comparison of the clinical and psychological effects of diazepam and amylobarbitone in anxious patients. Br J Clin Pharmacol. 1979; 7(6): 605–611.
   PubMedGoogle Scholar
• Kales A, Scharf MB, Kales JD, Soldatos CR. Rebound insomnia. A potential hazard following withdrawal of certain benzodiazepines. JAMA. 1979; 241(16): 1692–1695.
   PubMed Web of Science ®Google Scholar
• Monti JM, Attali P, Monti D, Zipfel A, de la Giclais B, Morselli PL. Zolpidem and rebound insomnia—a double-blind, controlled Polysomnographie study in chronic insomniac patients. Pharmacopsychiatry. 1994; 27(4): 166–175.
   PubMedGoogle Scholar
• Terzano MG, Rossi M, Palomba V, Smerieri A, Parrino L. New drugs for insomnia: comparative tolerability of zopiclone, Zolpidem and zaleplon. Drug Safi 2003; 26(4): 261–282.
   Google Scholar
• Ramakrishnan K, Scheid DC. Treatment options for insomnia. Am Fam Physician. 2007; 76(4): 517–526.
   PubMed Web of Science ®Google Scholar
• Scharf M, Erman M, Rosenberg R, et al. A 2-week efficacy and safety study of eszopiclone in elderly patients with primary insomnia. Sleep. 2005; 28(6): 720–727.
   PubMed Web of Science ®Google Scholar
• Griffiths RR, Johnson MW. Relative abuse liability of hypnotic drugs: a conceptual framework and algorithm for differentiating among compounds. J Clin Psychiatry. 2005; 66(suppl 9): 31–41.
   PubMed Web of Science ®Google Scholar
• Malmivaara A, Heliovaara M, Knekt P, Reunanen A, Aromaa A. Risk factors for injurious falls leading to hospitalization or death in a cohort of 19,500 adults. Am J Epidemiol. 1993; 138(6): 384–394.
   PubMed Web of Science ®Google Scholar
• Allain H, Bentue-Ferrer D, Polard E, Akwa Y, Patat A. Postural instability and consequent falls and hip fractures associated with use of hypnotics in the elderly: a comparative review. Drugs Aging. 2005; 22(9): 749–765.
   PubMed Web of Science ®Google Scholar
• Erman MK. Therapeutic options in the treatment of insomnia. J Clin Psychiatry. 2005; 66(suppl 9): 18–23; quiz 42–43.
   PubMedGoogle Scholar
• Roth T, Roehrs TA. Issues in the use of benzodiazepine therapy. J Clin Psychiatry. 1992; 53(suppl): 14–18.
   PubMedGoogle Scholar
• Nicholson AN. The use of short- and long-acting hypnotics in clinical medicine. Br J Clin Pharmacol. 1981; 11 (suppl 1): 61S-69S.
   Google Scholar
• Drover DR. Comparative pharmacokinetics and pharmacodynamics of short-acting hypnosedatives: zaleplon, Zolpidem and zopiclone. Clin Pharmacokinet. 2004; 43(4): 227–238.
   PubMedGoogle Scholar
• Johnson LC, Chernik DA. Sedative-hypnotics and human performance. Psychopharmacology (Berl). 1982; 76(2): 101–113.
   PubMedGoogle Scholar
• Sanger DJ, Zivkovic B. Differential development of tolerance to the depressant effects of benzodiazepine and non-benzodiazepine agonists at the omega (BZ) modulatory sites of GABAA receptors. Neuropharmacology. 1992; 31(7): 693–700.
   PubMed Web of Science ®Google Scholar
• Saper CB, Chou TC, Scattimeli TE. The sleep switch: hypothalamic control of sleep and wakefulness. Trends Neurosci. 2001; 24(12): 726–731.
   PubMed Web of Science ®Google Scholar
• Rudolph U, Crestani F, Benke D, et al. Benzodiazepine actions mediated by specific gamma-aminobutyric acid(A) receptor subtypes. Nature. 1999; 401(6755): 796–800.
   PubMed Web of Science ®Google Scholar
• Gorenstein C, Gentil V. Residual and acute effects of flurazepam and triazolam in normal subjects. Psychopharmacology (Beri). 1983; 80(4): 376–379.
   PubMedGoogle Scholar
• Muraoka M, Tada K, Nogami Y, Ishikawa K, Nagoya T. Residual effects of repeated administration of triazolam and nitrazepam in healthy volunteers. Neuropsychobiology. 1992; 25(3): 134–139.
   PubMedGoogle Scholar
• Korpi ER, Mattila MJ, Wisden W, Luddens H. GABA(A)-receptor subtypes: clinical efficacy and selectivity of benzodiazepine site ligands. Ann Med. 1997; 29(4): 275–282.
   PubMed Web of Science ®Google Scholar
• Ashton H. Guidelines for the rational use of benzodiazepines. When and what to use. Drugs. 1994; 48(1): 25–40.
   PubMed Web of Science ®Google Scholar
• Vgontzas AN, Kales A, Bixler EO. Benzodiazepine side effects: role of pharmacokinetics and pharmacodynamics. Pharmacology. 1995; 51(4): 205–223.
   PubMed Web of Science ®Google Scholar
• Sanger DJ, Benavides J, Perrault G, et al. Recent developments in the behavioral pharmacology of benzodiazepine (omega) receptors: evidence for the functional significance of receptor subtypes. Neurosci BiobehavRev. 1994; 18(3): 355–372.
   PubMedGoogle Scholar
• Lydiard RB, Lankford DA, Seiden DJ, Landin R, Farber R, Walsh JK. Efficacy and tolerability of modified-release indiplon in elderly patients with chronic insomnia: results of a 2-week double-blind, placebo-controlled trial. J Clin SleepMed. 2006; 2(3): 309–315.
   PubMed Web of Science ®Google Scholar
• Perrault G, Morel E, Sanger DJ, Zivkovic B. Differences in pharmacological profiles of a new generation of benzodiazepine and nonbenzodiazepine hypnotics. Eur J Pharmacol. 1990; 187(3): 487–494.
   PubMedGoogle Scholar
• Rosenberg R, Roth T, Scharf MB, Lankford DA, Farber R. Efficacy and tolerability of indiplon in transient insomnia. J Clin Sleep Med. 2007; 3(4): 374–379.
   PubMed Web of Science ®Google Scholar
• Salva P, Costa J. Clinical pharmacokinetics and pharmacodynamics of Zolpidem. Therapeutic implications. Clin Pharmacokinet. 1995; 29(3): 142–153.
   PubMed Web of Science ®Google Scholar
• Walsh JK, Moscovitch A, Burke J, Farber R, Roth T. Efficacy and tolerability of indiplon in older adults with primary insomnia. Sleep Med. 2007; 8(7–8): 753–759.
   PubMed Web of Science ®Google Scholar
• Savić MM, Obradović DI, Ugresić ND, Bokonjić DR. Memory effects of benzodiazepines: memory stages and types versus binding-site subtypes. Neural Plast. 2005; 12(4): 289–298.
   PubMedGoogle Scholar
• Lieberman JA. Update on the safety considerations in the management of insomnia with hypnotics: incorporating modified-release formulations into primary care. Prim Care Companion J Clin Psychiatry. 2007; 9(1): 25–31.
   PubMedGoogle Scholar
• Besset A, Tafti M, Villemin E, Borderies P, Billiard M. Effects of Zolpidem on the architecture and cyclical structure of sleep in poor sleepers. Drugs Exp Clin Res. 1995; 21(4): 161–169.
   PubMedGoogle Scholar
• Roth T, Roehrs T, Vogel G. Zolpidem in the treatment of transient insomnia: a double-blind, randomized comparison with placebo. Sleep. 1995; 18(4): 246–251.
   PubMedGoogle Scholar
• Scharf MB, Roth T, Vogel GW, Walsh JK. A multicenter, placebo- controlled study evaluating Zolpidem in the treatment of chronic insomnia. J Clin Psychiatry. 1994; 55(5): 192–199.
   PubMed Web of Science ®Google Scholar
• Uchimura N, Nakajima T, Hayash K, et al. Effect of Zolpidem on sleep architecture and its next-morning residual effect in insomniac patients: a randomized crossover comparative study with brotizolam. Prog Neuropsychopharmacol Biol Psychiatry. 2006; 30(1): 22–29.
   PubMedGoogle Scholar
• Erman M, Young T, Patel S, Neubauer D. The role of modified-release formulations in hypnotic therapy for insomnia. CNS Spectr. 2005; 10(6): 1–16.
   Google Scholar
• Weinling E, McDougall S, Andre F, Bianchetti G, Dubruc C. Pharmacokinetic profile of a new modified release formulation of Zolpidem designed to improve sleep maintenance. Fundam Clin Pharmacol. 2006; 20(4): 397–403.
   PubMedGoogle Scholar
• Hindmarch I, Stanley N, Legangneux E, Emegbo S. Zolpidem modified- release 12.5 mg improves measures of sleep continuity in a model of sleep disturbance (traffic noise) compared with standard Zolpidem 10 mg. Pharmacotherapy. 2005; 25: 1504.
   Google Scholar
• Blin O, Micallef J, Audebert C, Legangneux E. A double-blind, placebo- and flurazepam-controlled investigation of the residual psychomotor and cognitive effects of modified release Zolpidem in young healthy volunteers. J Clin Psychopharmacol. 2006; 26(3): 284–289.
   PubMedGoogle Scholar
• Hindmarch I, Legangneux E, Stanley N, Emegbo S, Dawson J. A doubleblind, placebo-controlled investigation of the residual psychomotor and cognitive effects of zolpidem-MR in healthy elderly volunteers. Br J Clin Pharmacol. 2006; 62(5): 538–545.
   PubMed Web of Science ®Google Scholar
• Roth T, Soubrane C, Titeux L, Walsh JK. Efficacy and safety of zolpidem-MR: a double-blind, placebo-controlled study in adults with primary insomnia. Sleep Med. 2006; 7(5): 397–406.
   PubMed Web of Science ®Google Scholar
• Walsh JK, Soubrane C, Roth T. Efficacy and safety of Zolpidem extended release in elderly primary insomnia patients. Am J Geriatr Psychiatry. 2008; 16(1): 44–57.
   PubMedGoogle Scholar
• Krystal AD, Erman M, Zammit GK, Soubrane C, Roth T. Long-term efficacy and safety of Zolpidem extended-release 12.5 mg, administered 3 to 7 nights per week for 24 weeks, in patients with chronic primary insomnia: a 6-month, randomized, double-blind, placebo-controlled, parallel-group, multicenter study. Sleep. 2008; 31 (1): 79–90.
   PubMed Web of Science ®Google Scholar
• Sanna E, Busonero F, Talani G, et al. Comparison of the effects of zaleplon, Zolpidem, and triazolam at various GABA(A) receptor subtypes. Eur J Pharmacol. 2002; 451(2): 103–110.
   PubMed Web of Science ®Google Scholar